| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg |
| ln Vivo |
Quercetin-3-O-sambubioside (50-400 mg/kg; gavage) promotes stimulation of nerve centers [1].
1. Effect on spontaneous activity in mice: Male ICR mice (weighing 20-22g) were randomly divided into a control group (administered with 0.5% sodium carboxymethyl cellulose, CMC-Na) and three Quercetin 3-Sambubioside treatment groups (doses: 50, 100, 200mg/kg), with 10 mice per group. Quercetin 3-Sambubioside was suspended in 0.5% CMC-Na and administered via intraperitoneal injection (ip). Thirty minutes after administration, each mouse was placed in a spontaneous activity recorder, and the number of spontaneous activities within 10 minutes was recorded. The results showed that compared with the control group, the number of spontaneous activities was significantly reduced in the Quercetin 3-Sambubioside 200mg/kg group (P<0.05), while the 50mg/kg and 100mg/kg groups had no significant effect on the spontaneous activity of mice[1] 2. Effect on convulsion rate in mice: Following the same grouping and administration protocol as the spontaneous activity experiment, thirty minutes after the administration of Quercetin 3-Sambubioside, mice were injected ip with pentylenetetrazol (80mg/kg) to induce convulsions. The incidence of convulsions and the number of deaths in each group within 30 minutes were observed. The results showed that compared with the control group, there were no statistically significant differences in the convulsion incidence and mortality rate among all Quercetin 3-Sambubioside treatment groups, indicating that the compound had no obvious anticonvulsant effect at the experimental doses[1] . |
|---|---|
| Animal Protocol |
Animal/Disease Models: Male Kunming mice [1]
Doses: 50, 100, 200, 400 mg/kg Route of Administration: gastric gavage. Experimental Results: Low dose stimulates the nerve center, enhances excitement, and does not cause convulsions. 1. Experimental animals: Healthy male ICR mice weighing 20-22g were used. The mice were housed under controlled temperature and humidity conditions, with free access to food and water; 2. Grouping and administration: Mice were randomly divided into 4 groups (10 mice per group), including a control group and three Quercetin 3-Sambubioside treatment groups (50, 100, 200mg/kg). Quercetin 3-Sambubioside was triturated and suspended in 0.5% CMC-Na, and the control group was given an equal volume of 0.5% CMC-Na. All administrations were performed via intraperitoneal injection (ip); 3. Detection of spontaneous activity: Thirty minutes after administration, each mouse was individually placed in the detection chamber of a spontaneous activity recorder. After a 2-minute adaptation period, the number of horizontal activities of the mice within 10 minutes was recorded to evaluate spontaneous activity; 4. Convulsion induction and observation: Under the same administration protocol as the spontaneous activity experiment, thirty minutes after the administration of Quercetin 3-Sambubioside, mice in each group were injected ip with pentylenetetrazol (80mg/kg) to establish a convulsion model. After the injection of pentylenetetrazol, observations were continued for 30 minutes to record the number of mice with tonic convulsions and the number of deaths, and finally the convulsion incidence and mortality rate were calculated[1] . |
| References |
|
| Additional Infomation |
Quercetin 3-O-[β-D-xylosyl-(1->2)-β-D-glucoside] is a quercetin O-glucoside with a structure in which quercetin is linked to a β-D-morulasoyl residue at position 3 via a glycosidic bond. It possesses antioxidant properties and is also a plant metabolite. It is a quercetin O-glucoside, a disaccharide derivative, and a tetrahydroxyflavonoid. Quercetin 3-morulasoylside has been reported to exist in Euphorbia prostrata, Oldenlandia herbacea var. herbacea, and other organisms with relevant data. 1. Quercetin 3-morulasoylside is a flavonoid compound isolated from the male flowers of Eucommia ulmoides. The core objective of this study is to investigate the effects of this compound on the central nervous system of mice, with particular attention to its regulatory effect on spontaneous activity and potential anticonvulsant activity;
2. Experimental results showed that quercetin-3-morulatoside significantly inhibited spontaneous activity in mice only at high doses (200 mg/kg), suggesting that it has a potential sedative effect on the central nervous system. However, no significant anticonvulsant effect was observed in the dose range of 50-200 mg/kg, indicating that the anticonvulsant potential of this compound is limited[1] . |
| Molecular Formula |
C26H28O16
|
|---|---|
| Molecular Weight |
596.4909
|
| Exact Mass |
596.138
|
| CAS # |
83048-35-5
|
| PubChem CID |
5487635
|
| Appearance |
White to off-white solid
|
| Boiling Point |
999.0±65.0 °C at 760 mmHg
|
| LogP |
-1.2
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
42
|
| Complexity |
993
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O([C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C1C(=O)C2C(=CC(=CC=2OC=1C1C=CC(O)=C(O)C=1)O)O
|
| InChi Key |
NKFZLEYLWAFYEH-CJNLAGEVSA-N
|
| InChi Code |
InChI=1S/C26H28O16/c27-6-15-18(34)20(36)24(42-25-21(37)17(33)13(32)7-38-25)26(40-15)41-23-19(35)16-12(31)4-9(28)5-14(16)39-22(23)8-1-2-10(29)11(30)3-8/h1-5,13,15,17-18,20-21,24-34,36-37H,6-7H2/t13-,15-,17+,18-,20+,21-,24-,25+,26+/m1/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~209.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6765 mL | 8.3824 mL | 16.7647 mL | |
| 5 mM | 0.3353 mL | 1.6765 mL | 3.3529 mL | |
| 10 mM | 0.1676 mL | 0.8382 mL | 1.6765 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
